Prophylaxis and treatment of hepatitis C;Prophylaxie et traitement de l'hépatite C

Bulletin de l'Academie Nationale de Medecine

Volumn 180, Issue 6, 1996, Pages 1279-1292

  Poupon, Raoul ^b   Serfaty, Lawrence ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b NONE

Author keywords

Hepatitis C, drug therapy; Interferon alfa 2A; Interferon alfa 2B

Indexed keywords

ANTIVIRUS AGENT; RECOMBINANT INTERFERON;

ACUTE DISEASE; HEPATITIS C; HUMAN; PROGNOSIS; REVIEW;

ACUTE DISEASE; ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; INTERFERON TYPE I, RECOMBINANT; PROGNOSIS;

EID: 0030155862     PISSN: 00014079     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Rapport Micoud. L'hépatite C en France, 1992.
2. DHUMEAUX D., ROUDOT-THORAVAL F., PAWLOTSKY J.M. - Enquête épidémiologique sur la prévalence, la gravité et les facteurs de risque des lésions chroniques du foie induites par le virus de l'hépatite C en France, 27 mai 1994.
3. TINE F., MAGRIN S., CRAXI A., PAGLIARO L. - Interferon for chronic non-A, non-B hepatitis : a meta-analysis of randomized clinical trials. J Hepatol, 1991, 13, 192-199.
4. HOOFNAGLE J.H., MULLEN K.D., JONES D.B., RUSTGI V., DIBISCEGLIE A.M., PETERS M. et al. - Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. N Engl J Med, 1986, 315, 1575-1578.
5. CHOO Q.L., KUO G., WEINER A.J., OVERBY L.R., BRADLEY D.W., HOUGHTON M. - Isolation of cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 1989, 244, 359-362.
6. KNODELL R.G., ISHAK K.G., BLACK W.C., CHEN T.S., CRAIG R., KAPLOWITZ N. et al. - Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology, 1981, 1, 431-435.
7. The French Metavir Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology, 1994, 20, 15-20.
8. SARACCO G., ROSINA F., ABATE M.L., CHIANDUSSI L., GALLO V., CERUTTI E. et al. - Long-term follow-up of patients with chronic hepatitis C treated with different doses of Interferon a-2b. Hepatology, 1993, 18, 1300-1305.
9. JOUET P., ROUDOT-THORAVAL F., DHUMAUX D., METREAU J.M., and le Groupe Français pour l'Etude du Traitement des Hépatites Chroniques NANB/C. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with Non-A, Non-B, C hepatitis. Gastroenterology, 1994, 106, 686-690.
10. CHEMELLO L., BONETTI P., CAVALLETTO L., TALATO F., DONADON V., CASARIN P. et al. - Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology, 1995 22, 700-706.
11. DIODATI G., BONETTI P., NOVENTA F., CASARIN C., RUGGE M., SCACCABAROZZI S. et al. -Treatment of chronic hepatitis C with recombinant human interferon-alfa2a : results of a randomized controlled clinical trial. Hepatology, 1994, 19, 1-5.
12. NOBORU M., CHEVALLIER M., CHOSSEGROS P., CAUSSE X., GUERET S., TREPO C., GRIMAUD J.A. - Interferon-alfa2b therapy reduces liver fibrosis in chronic Non-A, Non-B hepatitis : a quantitative histological evaluation. Hepatology, 1993, 18, 1344-49.
13. NISHIGUCHI S., KUROKI T., NAKATANI S., MORIMOTO H., TAKEDA T., NAKAJIMA S. et al. - Randomised trial of effects of interferon-alfa on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet, 1995, 346, 1051-55.
14. MARCELLIN P., POUTEAU M., BENHAMOU J.P. - Hepatitis C virus infection, alfa interferon therapy and thyroid dysfunction. J Hepatol, 1995, 22, 364-369.
15. JANSSEN H.L.A., BROUWER J.T., VAN DER MAST R.C., SCHALM S.W. - Suicide associated with alfa interferon therapy for chronic viral hepatitis. J Hepatol, 1994, 21, 241-243.
16. DAVIS G.L. - Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol, 1994, 21, 1-3.
17. SERFATY L., GIRAL P., LORIA A., ANDRÉANI T., LEGENDRE C., POUPON R. - Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol, 1994, 21, 12.
18. BASTIÉ A., ROUDOT-THORAVAL F., PAWLOTSKY J.M., PELLET C., BABANY G., LEMMONIER C. et al. - L'interferon alpha doit-il être prescrit selon une posologie adaptée à la surface corporelle lors du traitement des hépatites chroniques C ? (résumé). Gastroenterol Clin Biol, 1995, 19, A182.
19. MARTINOT-PEIGNOUX M., MARCELLIN P., POUTEAU M., CASTELNAU C., BOYER N., POLIQUIN M. et al. - Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main independent pronostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology, 1995, 22, 1050-1056.
20. ENOMOTO N., SAKUMA I., ASAHINA Y., KUROSAKI M., MURAKAMI T., YAMAMOTO C. et al. - Mutation in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med, 1996, 334, 77-81.
21. KOIZUMI K., ENOMOTO N., KUROSAKI M., MURAKAMI T., IZUMI N., MARUMO F. et al - Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology, 1995, 22, 30-35.
22. OUZAN D., SKAF R., ANDRÉANI T., OPOLON P., TRÉPO C., MICHEL P. et al. - L'activité sérique de l'ALT après un mois de traitement est-elle le meilleur facteur prédictif de réponse à l'interferon alpha-2A dans l'hépatite chronique C ? Analyse multivariée chez 295 patients (résumé). Gastroenterol Clin Biol, 1993, 17, 687.
23. POL S., JAFFREDO F., NALPAS B., SAYADA C., BERTHELOT P., BRÉCHOT C. - Conduite pragmatique du traitement par interféron-alfa (IFN) des hépatites chroniques C (résumé). Gastroenterol Clin Biol, 1995, 19, A184.
24. ROFFI L., COLLOREDO M., ANTONELLI G., BELLATI G., PANIZZUTI F., PIPERNO A. et al. - Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection : prevalence, etiology, and management. Hepatology, 1995, 21, 645-649.
25. MARCELLIN P., POUTEAU M., MARTINOT-PEIGNOUX M., DEGOS F., DUCHATELLE V., BOYER N. et al. - Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology, 1995, 109, 156-165.
26. ANDREONE P., CURSARO C., GRAMENZI A., BUZZI A., MINIERO R., SPOVIERI G. et al. - Indomethacin enhances serum 2′5′-oligoadenylate synthetase in patients with hepatitis B and C virus chronic active hepatitis infection. J Hepatol, 1994, 21, 984-988.
27. BOUCHER E., JOUANOLLE H., ANDRÉ P., RUFFAULT A., GUYADER D., MOIRAND R. et al. - Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis : results from a controlled randomized trial in 80 patients. Hepatology, 1995, 21, 322-327.
28. HAN SH., FONG T.L., VALINLUCK B., ADKINS R.H., REDEKER A.G. - Randomized controlled trial of the effect of iron depletion on aminotransferase levels., HCV RNA and response to interferon therapy in patients with chronic hepatitis in patients with chronic hepatitis C (abstract). Hepatology, 1995, 22, 180A.
29. CHEMELLO L., CAVALLETTO L., BERNARDINELLO E., SILVESTRI E., BENVEGNU L., PONTISSO P. et al. - Response to ribavirin, to interferon and to a combination of both in patients with chronic hepatitis C and its relation to HCV genotypes (abstract). J Hepatol, 1994, S12.
30. MARCELLIN P., POUTEAU M., BOYER N., CASTELNAU C., ERLINGER S., BENHAMOU J.P. - Retreatment with recombinant interferon-alpha in patients with chronic hepatitis C. J Infect Dis, 1993, 167, 780-781.
31. BRILLANTI S., GARSON J., FOLI M., WHITBY K., DEAVILLE R., MASCI C., MIGLIOLI M., BARBARA L. - A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology, 1994, 107, 812-817.
32. GANE E.J., PORTMANN B.C., NAOUMOV N.V., SMITH H.M., UNDERHILL J.A., DONALDSON P.T., et al. - Long term outcome of hepatitis C infection after liver transplantation. N Engl J Med, 1996, 334, 815-820.
33. FÉRAY C., SAMUEL D., GIGOU M., PARADIS V., DAVID M.F., LEMONNIER C., REYNES M., BISMUTH H. - An open trial of interferon alfa recombinant for hepatitis C after liver transplantation : antiviral effects and risk of rejection. Hepatology, 1995, 22, 1084-1089.
34. BIZOLLON T., DUCERF C., SCIARINNO E., CHEVALIER M., PALAZZO U., BAULIEUX J. et al. - Mise en rémission complète durable de l'hépatite C par réinfection du greffon hépatique grâce àun traitement précoce associant IFN-ribavirine suivi de ribavirine seule (résumé). Gastroenterol Clin Biol, 1995, 20, 79.
35. POL S., THERVET E., LEGENDRE C., GAGNADOUX M.F., BERTHELOT P., KREIS H. - Traitement par interféron alpha 2b (IFN) des infections virales C chez les transplantés rénaux : étude-pilote (résumé). Gastroenterol Clin Biol, 1995, 19, 86.
36. POL S., THIERS V., CARNOT F., ZINS B., ROMEO R., BERTHELOT P., BRÉCHOT C. - L'interféron alpha 2b (IFN) est efficace chez les hémodialysés infectés par le VHC (résumé). Gastroenterol Clin Biol, 1995, 19, 88.
37. GARCIA-SAMANIEGO J., SORIANO V., BRAVO R., MARTINEZ-ODRIOZOLA P., GONZALEZ J., CASTRO A. et al. - Efficacy and safety of alpha-interferon therapy for chronic hepatitis C in HIV+ patients (abstract). Hepatology, 1994, 20, 162A.
38. BORTOLOTTI F., GIACCHINO R., VAJRO P., BARBERA C., CRIVELLARO C., ALBERTI A. et al. - Recombinant interferon-alfa therapy in children with chronic hepatitis C. Hepatology, 1995, 22, 1623-1627.
39. SERFATY L., CHAZOUILLÉRES O., PAWLOTSKY J.M., ANDREANI T., PELLET C., POUPON R. - Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gaslroenterology, 1996, 110, 291-295.
40. TAKANO S., ITO Y., YOKOSUKA O., OHTO M., UCHIUMI K., HIROTA K. et al. - A muticenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology, 1994, 20, 558-564.
41. DI BISCEGLIE A.M., SHINDO M., FONG T.L., FRIED M.W., SWAIN M.G., BERGASA N.V. et al. - A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology, 1992, 16, 649-654.
42. HAYASHI H., TAKIKAWA T., NISHIMURA N., YANO M. - Serum aminotransferase levels as an indicator of effectiveness of venesection for chronic hepatitis C. J Hepatol, 1995, 22, 268-271.
43. LAMPERTICO P., RUMI M., ROMEO R., CRAXI A., SOFFREDINI R., BIASSONI D. et al. - A muticenter randomized controlled trial of recombinant interferon-alfa2b in patients with acute transfusion-associated hepatitis C. Hepatology, 1994, 19, 19-22.
44. KRAWCZYNSKI K., ALTER M.J., TANKERSLEY D.L., LAMBERT S., MEEKS E., BEACH M. et al. - Studies on protective efficacy of hepatitis C immunoglobulins (HCIG) in experimental hepatitis C virus infection (abstract). Hepatology, 1993, 18, 110A.
45. YOO B.J., SELBY M.J., CHOE J., SUH B.S., CHOI S.H., JOH J.S. et al. - Transfection of a diffentiated human hepatoma cell line (Huh7) with in vitro-transcribed hepatitis C virus (HCV) RNA and establishment of a long-term culture persistently infected with HCV. J Vitol, 1995, 69, 32-38.